Poster Presentations 2017
DOI: 10.1136/annrheumdis-2017-eular.1302
View full text |Buy / Rent full text
|
Sign up to set email alerts
|

Abstract: BackgroundAnkylosing spondylitis (AS) patients (pts) were found to respond better to TNF inhibitors (TNFi) if treated early in the disease course.1 The actual disease onset and hence disease duration is not always known. Previously, younger age was found to have the largest positive impact on clinical outcomes following 12 weeks (wks) of adalimumab (ADA) treatment.2ObjectivesThe objective of this analysis was to examine the impact of time since diagnosis, age, and number of prior NSAIDs as surrogates for disea… Show more

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles